US Stock MarketDetailed Quotes

PSTX Poseida Therapeutics

Watchlist
  • 2.864
  • +0.154+5.68%
Trading Nov 22 13:38 ET
279.14MMarket Cap-4546P/E (TTM)
Intraday
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Nov 5 15:21
    NEWS
    $Poseida Therapeutics (PSTX.US)$
    Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024
    New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC
    Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH
    SAN DIEGO, Nov. 5, 2024 /PRN...
    Jaguar8
    Jaguar8
    Sep 27 15:33
    NEWS
    $Poseida Therapeutics (PSTX.US)$
    Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
    Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality
    Differentiated P-BCMA-ALLO1 ...
    Jaguar8
    Jaguar8
    Sep 16 07:05
    NEWS
    $Poseida Therapeutics (PSTX.US)$
    Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
    FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society Annual Meeting this month
    RMAT designation recognizes potential of P-BCMA-ALLO1 to address significant u...
    2
    Jaguar8
    Jaguar8
    Sep 5 08:01
    NEWS
    $Poseida Therapeutics (PSTX.US)$
    Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
    Poseida Therapeutics (Nasdaq: PSTX) will present new clinical data from its ongoing Phase 1 study of P-BCMA-ALLO1, an investigational off-the-shelf allogeneic CAR-T cell therapy for relapsed/refractory multiple myeloma, at the 21st International Myeloma S...
    Jaguar8
    Jaguar8
    May 1 12:31
    $Poseida Therapeutics (PSTX.US)$
    NEWS
    Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data